Last $68.56 USD
Change Today +1.23 / 1.83%
Volume 7.5M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Open
$67.81
Previous Close
$67.33
Day High
$69.98
Day Low
$67.02
52 Week High
01/13/15 - $75.24
52 Week Low
05/9/14 - $22.25
Market Cap
8.1B
Average Volume 10 Days
2.7M
EPS TTM
$-0.21
Shares Outstanding
118.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISIS PHARMACEUTICALS INC (ISIS)

isis pharmaceuticals inc (ISIS) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

365 Employees
Last Reported Date: 03/3/14
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $581.4K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.2M
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Senior Vice President of Development
Total Annual Compensation: $624.4K
Compensation as of Fiscal Year 2013.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

Isis Pharmaceuticals, Inc. announced positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE). HAE is a severe and rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE affects approximately 20,000 patients in the United States and Europe and can be fatal if swelling occurs in the airway. The Phase 1 study of ISIS-PKKRx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-PKKRx. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After only 3 weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33%, 69%, 87% and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.

Isis Pharmaceuticals, Inc. expected to report Fiscal Year 2014 results on February 26, 2015. This event was calculated by Capital IQ (Created on February 22, 2015).

Isis Pharmaceuticals, Inc. expected to report Fiscal Year 2014 results on February 26, 2015. This event was calculated by Capital IQ (Created on February 22, 2015).

Isis Pharmaceuticals, Inc., 2014 Earnings Call, Feb 27, 2015

Isis Pharmaceuticals, Inc., 2014 Earnings Call, Feb 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $68.56 USD +1.23

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $37.97 USD +0.19
Acorda Therapeutics Inc $33.84 USD -1.72
Depomed Inc $21.95 USD -0.65
Galena Biopharma Inc $1.80 USD -0.03
Tekmira Pharmaceuticals Corp C$22.55 CAD -0.34
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.2x
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.